Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

The 25-year-old joint commitment among established providers of official development assistance (ODA) to invest in efforts ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he may no longer allow government ...

Books are fundamental to Zackie Achmat's life. The health and political activist whose name is synonymous with civil disobedience and who helped lead the mass protests that won access to affordable ...

Hiding behind numerous disguises, HIV has been evading researchers for years, leaving the search for a vaccine as elusive as the virus itself. Once believed to exist as pure strains or subtypes ...

In this open-label trial with a 2-by-4 factorial design, we randomly assigned children with HIV who had first-line treatment failure to receive second-line therapy with tenofovir alafenamide ...

The number of children living with HIV who require second-line ART is increasing. Which drugs are safest and most effective for pediatric second-line ART is unknown. New research findings are ...

Multipurpose prevention technologies (MPTs) are multi-indication products commonly focusing on the prevention of unintended pregnancy, HIV, and/or other sexually transmitted infections (STIs). MPTs ...

The study, published in The Lancet Healthy Longevity journal, reveals that HIV prevalence among older adults now surpasses that of younger individuals. Dr. Louiser Olubayo of the Sydney Brenner ...